May 2nd 2024
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
February 27th 2024
February 18th 2024
What Is Your Experience With Regorafenib?
September 16th 2016If you’ve been in oncology long enough, you’ve likely seen the patient who presents with metastatic disease, gets first-line therapy, progresses, switches to second-line therapy, progresses again, and so on, with their cancer becoming increasingly more resistant to therapy.
Improving Outcomes in Resectable Gastric Cancer: A Review of Current and Future Strategies
Here we review the evidence supporting current approaches to resectable gastric cancer, including discussion of the optimal extent of surgery and lymphadenectomy, adjuvant chemotherapy, postoperative chemotherapy with chemoradiation, and perioperative chemotherapy.
Adjunctive Therapy of Gastric Cancer: Moving the Field Forward
July 15th 2016Current methods of treatment still have a small impact on the survival of patients with localized disease. Improved understanding of the underlying mutations seen in gastric cancer might suggest alternative treatments and ways to better select patients.
Dietary Factors Linked to Changes in Gastric Cancer Risk
November 23rd 2015A meta-analysis found that a number of dietary factors play a role in the risk of developing gastric cancer, with protective effects seen with fruit and certain vegetables and increased risk seen with high-salt foods and certain forms of alcohol.
New Targeted Treatment IMMU-130 for Patients With Metastatic Colon Cancer
May 29th 2015New data suggests that an experimental targeted therapy known as IMMU-130 may be effective in controlling drug-resistant metastatic colorectal cancer (mCRC) in patients previously treated with irinotecan-containing chemotherapy regimens.
Subacute Headache in a Patient With Metastatic Gastric Cancer
May 15th 2015A 59-year-old man with metastatic gastric cancer presented to the oncology clinic with a 1-week history of positional headache, nausea, and vomiting. He stated that the headache was located in the frontal region, was 8 on a scale of 10 in intensity.
Esophagogastric Junction and Gastric Adenocarcinoma: Current Challenges and Future Directions
June 15th 2014Both esophageal cancer and stomach cancer are aggressive malignancies with contrasting risk factors, histologies, and molecular characteristics-yet for the most part comparable therapeutic approaches.